^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Pancreatic Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Prostate Cancer)
    New
    Title:

    Lynparza (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

    Excerpt:
    Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Olaparib in Treating Patients With Stage IV Pancreatic Cancer

    Excerpt:
    ...somatic BRCA mutation, Fanconi anemia gene, ATM or RAD51 mutations)...
    Trial ID:
    NCT02677038
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Res
    Title:

    ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage

    Excerpt:
    Supporting this possibility, we found that the PARP inhibitor olaparib or ATR inhibitors reduced the viability of PDAC cells in vitro and in vivo associated with a genotype-selective increase in apoptosis. Overall, our results offered a preclinical mechanistic rationale for the use of PARP and ATR inhibitors to improve treatment of ATM-mutant PDAC. 
    DOI:
    10.1158/0008-5472.CAN-17-0634